Phase 4 trials have proven to be notoriously difficult for large pharma sponsors and CROs, who often struggle to recruit and retain the necessary patient population. Learn how digital trial solutions that leverage RWD can improve the quality of outcomes and patient experiences during these studies.
It’s no secret that Phase 4 trials are incredibly time consuming, costly, and pose major challenges for sponsors and CROs alike. Whether it’s Long Term Follow Up (LTFU), Rollover, and Observational studies, or Registry and Consumer Health studies, sponsors often struggle to recruit and retain large numbers of participants. They also have difficulties addressing post-marketing commitments to assess long term drug safety and efficacy.
For a fraction of the cost, digital trial solutions (e.g., eConsent, eCOA, TeleVisit, Connected Sensors) combined with Real World Data (RWD) can solve traditional Phase 4 trial challenges while capturing the critical endpoint data needed for LTFU studies and informing future protocol designs and trial efficiencies.
In this webcast, Leader of TA Solutions at Medable, Musaddiq Khan, is joined by the Head of Real World Evidence Solutions at Syneos Health, Mike D’Ambrosio, and VP of Growth at Medable, Sam Bavery, to discuss how they have partnered to deploy patient-first digital trial solutions that leverage RWD, transforming it into actionable RWE insights for a sponsor client.
Key Learning Objectives:
Through this webcast, you will learn how to optimize digital trial solutions in Phase 4 and LTFU studies by:
Transforming RWD into actionable RWE insights that inform future trials
Improving patient safety with remote monitoring and real-time data access
Boosting patient engagement and retention to drive higher quality data capture
Leveraging similar study characteristics to standardize study build and accelerate deployment
Musaddiq Khan (“Muz”)
VP, Therapeutic Area Solutions
Musaddiq (“Muz”) has been involved in clinical research for over 17 years. Most recently, he was Director of Clinical Program Operations in the Exploratory Medicine & Pharmacology group at Eli Lilly, where he led the operational delivery of the First-in-Human study on Lilly’s COVID-19 Antibody programme. Throughout his career, Muz has held various clinical operations roles in pharma, including PAREXEL, Roche, and AstraZeneca.
Muz completed his Executive MBA from the University of Cambridge with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development.”
VP Growth & Strategy
Sam Bavery is the Senior Director of Strategy & Growth at Medable. In this role, Sam leads the effort to scale the use of digital capabilities with Medable’s customers and partners, focusing on standardization and automation to drive cycle time reduction and increase data quality. Prior to joining Medable in 2021, Sam spent over a decade at Accenture working in roles that span across the healthcare ecosystem – with a focus on developing solutions that bridge the gap between standards of care and clinical trials. Most recently, he led teams with multiple top 20 pharma companies in driving DCT strategies. Sam holds a Bachelor of Science degree in Computer Engineering from the University of Minnesota.